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Abstract
The limited ability of common variants to account for the genetic contribution to complex disease has prompted searches for rare
variants of large effect, to partly explain the ‘missing heritability’. Analyses of genome-wide genotyping data have identified
genomic structural variants (GSVs) as a source of such rare causal variants. Recent studies have reported multiple GSV loci
associated with risk of obesity. We attempted to replicate these associations by similar analysis of two familial-obesity case-control
cohorts and a population cohort, and detected GSVs at 11 out of 18 loci, at frequencies similar to those previously reported. Based
on their reported frequencies and effect sizes (OR$25), we had sufficient statistical power to detect the large majority (80%) of
genuine associations at these loci. However, only one obesity association was replicated. Deletion of a 220 kb region on
chromosome 16p11.2 has a carrier population frequency of 261024 (95% confidence interval [9.661025–3.161024]); accounts
overall for 0.5% [0.19%–0.82%] of severe childhood obesity cases (P=3.8610210; odds ratio=25.0 [9.9–60.6]); and results in a mean
bodymass index (BMI) increase of 5.8 kg.m22 [1.8–10.3] in adults from the general population. We also attempted replication using
BMI as a quantitative trait in our population cohort; associations with BMI at or near nominal significance were detected at two
further loci near KIF2B and within FOXP2, but these did not survive correction for multiple testing. These findings emphasise several
issues of importancewhen conducting rare GSV association, including the need for careful cohort selection and replication strategy,
accurate GSV identification, and appropriate correction for multiple testing and/or control of false discovery rate. Moreover, they
highlight the potential difficulty in replicating rare CNV associations across different populations. Nevertheless, we show that such
studies are potentially valuable for the identification of variants making an appreciable contribution to complex disease.
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Introduction
Genome-wide association studies (GWAS) of common single
nucleotide polymorphisms (SNPs) have identified loci accounting
for only a modest proportion of the heritability of most complex
diseases. Although some of this ‘missing heritability’ may be
ascribed to a large number of SNPs with weak effect [1,2], it is
becoming increasingly likely that there is a substantial contribution
from rare variants with large effect that are not readily identifiable
by SNP-based methods [3–5]. Thus, resequencing of known risk
loci has been pursued to reveal rare point mutations that may have
an appreciable impact on disease risk or severity[6–8].
We have recently proposed that investigation of genomic
structural variants (GSVs) in patients with ‘‘extreme’’ obese
phenotypes provides an effective route for the identification of
novel obesity-associated loci [9]. Initial reports indicate that
subjects with unexplained extreme obesity phenotypes may have a
higher aggregate frequency of large GSVs (e.g. .0.5 Mb)
compared to the general population [10,11], strongly suggesting
that some of the GSVs carried by these unusual patients are
responsible for a pronounced, readily-identifiable phenotype with
high penetrance. Genes within the regions delineated by such
GSVs may also be of direct relevance to obesity in the general
population.
In a first application of this strategy for the identification of
novel obesity loci, we showed that a 593 kb deletion on
chromosome 16p11.2 (at 29.5–30.1 Mb) directly causes obesity
[12]: this association was demonstrated by comparing two cohorts
with developmental delay (DD), with or without additional
ascertainment for obesity, and was then replicated by retrospective
analysis of case-control and population cohorts. We have also
shown that duplications of the same locus have the opposite effect,
being associated with underweight [13]. Several genes whose
altered dosage might plausibly account for the observed phenotype
lie within the deleted region, and their potential role in obesity can
now be investigated in a hypothesis-driven manner, rather than by
the more statistically-challenging hypothesis-free approach appli-
cable to GWAS. Indeed, there are no GWAS signals overlapping
this locus [14,15], illustrating the potential of strategies based on
identification of rare GSVs for the identification of novel obesity
loci.
A growing number of rare GSVs potentially associated with
obesity are now being reported, mainly on the basis of their
identification by analysis of GWAS SNP genotyping data.
Bochukova, et al. [10] compared a small cohort of ,300 patients
with severe early-onset obesity (half of whom also had develop-
mental delay, DD) with control individuals from the general
population, and identified 11 GSV regions that showed association
with obesity at nominal significance, including the obesity-
associated 593 kb region [12] of chromosome 16p11.2 which is
not further studied here. Glessner, et al. [16] identified 8 additional
GSV loci with nominally significant association with obesity, on
the basis of being present in children with ‘‘common’’ obesity
(individuals with severe obesity were excluded from the study) but
absent from control cohorts of normal weight. The GSVs
identified in these two studies vary widely in size, ranging from
2.8 kb to 1.5 Mb, with no overlap between them. With the
exception of the independently identified 593 kb deletion of
chromosome 16p11.2 [12,13], all remain to be replicated.
We have attempted to replicate these recently-reported GSV
associations with obesity, using algorithmic analysis of genotyping
data from obesity case-control and population cohorts. We
replicate association with obesity of GSVs at a single locus on
chromosome 16p11.2; this locus is distinct from the association on
16p11.2 which we previously reported (using the same cohorts),
being separated from it by .600 kb of intervening sequences; the
2 loci are independently associated with obesity. However, we
were unable to replicate a high proportion of the remaining
regions, and conclude that there is a need for the development and
application of robust statistical methods appropriate for testing for
association of rare variants from amongst a large collection of
GSVs, independent of the platform used for GSV detection. We
also highlight the caution required when attempting to support
putative associations by phenotyping affected subjects: phenotypic
data from a small number of individuals from a highly-selected
cohort may not be reliable as an indication of the impact of the
variant in unselected subjects.
Results
GSV Analysis of Obesity-associated Regions
To investigate the 18 putative associations with obesity reported
for rare GSVs [10,16] (see Table 1), we analysed population and
case-control cohorts in a similar manner to that successfully used
in our replication of the association with obesity of the 16p11.2
593 kb deletion [12]. Using existing genotyping data from cohorts
of severely obese (but with no other reported unrelated health
problem) French children and adults, similar numbers of non-
overweight controls, and a general population cohort from
northern Finland [17,18], each genomic region was analysed for
the presence of GSVs.
Initial identification of GSVs was carried out using our cnvHap
algorithm, which is applicable to data from a wide range of
platforms (including Illumina and Affymetrix genotyping arrays,
CGH arrays and next-generation sequencing), and which has
greatly improved sensitivity and specificity for detection of short
GSVs compared to other commonly-used algorithms [19]. To
ensure that our analysis mirrored the procedures that led to the
original reported associations, we scored only those GSVs that
were of a similar type (deletion/duplication) and that spanned the
entirety of the GSV region. In addition, to ensure that only high-
confidence calls were included, for the shorter candidate regions
(those for which we had probe coverage of 6 or fewer probes – see
Table 1) we required that a GSV call included a minimum of 3
consecutive probes in all cases, irrespective of the size of the region
being analysed.
This procedure was applied to our cohorts for each of the 18
loci under investigation (8 identified in subjects with common
obesity [16], 10 in subjects with extreme obesity [10]). Consistent
with the original reports, short GSV regions often featured
multiple overlapping aberrations with varying lengths and break-
points (see Figure 1); by contrast, aberrations identified for larger
GSV regions were much more consistent in both size and
breakpoint location. The results of the analysis, summarised in
Table 1, revealed somewhat different patterns of occurrence for
the 2 sets of GSVs. For the 8 GSVs originally identified in subjects
with common obesity, the overall frequency of calls at these loci in
our cohorts (63 calls in a total of 7959 subjects) was 25% higher
than that in the original report (42/6634), and GSVs at 6 out of 8
loci were detected at least twice. By contrast, the number of calls
(21 in total) for the 10 extreme obesity GSV loci represented a
30% lower frequency than in the original report (29/7650), and
only 5 out of 10 were detected at all: It was notable that the 5
detected were those originally identified only in subjects either
lacking DD or with only mild DD. The remaining 5 were
originally identified in subjects with pronounced DD [10], raising
the possibility that they were not detected because subjects
carrying them tended not to be recruited to our cohorts.
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We also investigated the occurrence of reciprocal GSVs at each
locus (i.e. duplications instead of deletions and vice versa), applying
the same calling criteria (Table S1). Although the overall
frequency of reciprocal GSVs was slightly lower compared to
those showing reported association with obesity, there was a
difference between the two sets of loci: Common obesity GSVs
were identified approximately twice as frequently as their
reciprocal counterparts, but extreme obesity GSVs were 30% less
frequent than reciprocal aberrations. For three GSV loci in
particular (those on chromosomes 3, 17 and 22), all originally
identified in subjects with DD, there was a clearly higher
frequency of the reciprocal event in population cohorts; this is
again consistent with the GSVs identified only in DD patients
having reduced prevalence in the general population.
Case-control Replication Analysis
Combining subjects from the population cohort who were obese
(BMI $30 kg.m22) or normal weight/underweight (BMI
,25 kg.m22) with the corresponding case-control subjects, and
assuming a GSV has a dominant effect, the combined cohort was
sufficient to give .98% power to detect associations (at P,0.05
for Fisher’s exact test) of GSVs present almost exclusively in obese
subjects (odds ratio, OR = 50) at a frequency in cases of 0.005, or
with power of 94% or 83% for odds ratios of 10 or 5 respectively;
even for a GSV frequency in cases of 0.002, power was 67%
(OR = 50), 53% (OR = 10) or 40% (OR = 5). On the basis of the
observed GSV frequencies and ORs in the original reports,
median power was 79.8% (minimum 53%) for the 11 loci for
which the corresponding GSVs were detected in our cohorts; thus,
we might expect to replicate ,80% of genuine associations.
Although this is likely to be something of an overestimate because
of OR overestimation due to the ‘‘winner’s curse’’ [20], the
minimum OR in the original reports was 25 [10,16]), and even for
much lower effect sizes with OR$5 we would nevertheless expect
to detect 62% of associations (71% of those with OR$10).
Although GSVs at these loci were observed at similar overall
frequencies to those in the original reports, we observed a low rate
of replication for associations with obesity (Table 1). For 10 of the
Figure 1. Procedure for identification of GSVs. Following data export and QC, GSV calling was carried out using the cnvHap algorithm.
Illustrative data for 3 GSV loci (shaded) show all positive GSV calls (black) together with examples of calls not meeting the necessary criteria (grey);
probes at which copy number changes were identified are also indicated (circles).
doi:10.1371/journal.pone.0058048.g001
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11 GSVs detected, the reported obesity association was not
replicated, even at nominal levels of significance. Of particular
note was that each of the 6 GSVs originally identified in subjects
with common obesity was present in at least 1 normal weight or
underweight individual, contrary to the criteria used to identify
these GSVs (i.e. being present exclusively in obese subjects) [16].
Indeed, for the majority of loci the GSV frequency was higher in
normal weight than in obese subjects.
For a single GSV, however, the association with obesity was
strongly replicated. A deletion of 220 kb on chromosome 16p11.2
(at 28.73–28.95 Mb) affecting several genes including SH2B1, was
identified in 6 obese individuals compared to none in normal
weight subjects (P= 5.4861024). This deletion spans a locus
implicated in obesity in SNP-association studies [14]. Of note,
apart from rare instances of more extensive deletions spanning
both regions [10,21], which complicated the previous analysis of
this region (see Text S1), this 220 kb region is completely separate
from the 593 kb locus (also on 16p11.2) whose association with
obesity/underweight has been previously reported by us [12,13];
they are 600 kb apart, there is no discernible linkage disequilib-
rium between SNPs within each region (Figure S1), and copy-
number changes at the 593 kb locus have no consistent effect on
expression of genes at the 220 kb locus [13]. Thus, each locus is
independently associated with obesity.
The Contribution of Chromosome 16p11.2 220 kb
Deletions to Obesity
Consistent with the original report for the SH2B1 locus [10], 5
of the affected subjects were from our cohort of severely obese
children, a significant enrichment compared to our general
population cohort (P= 1.461023). Extending the analysis to
include multiple other population cohorts (Table 2) unambigu-
ously confirmed the association between this deletion and
childhood obesity (P= 8.761027; OR = 38.4, [95% confidence
interval = 10.4–120.6]). This finding was further strengthened
(P= 3.8610210, OR = 25.0 [9.9–60.6]) by inclusion of previously
published data [10,21].
Intriguingly, the association with adult obesity is less clear. We
investigated by MLPA the parents of the 5 severely obese children
carrying the deletion, finding that 4 deletions were inherited (one
arising de novo). However, only two of the four adult carriers were
obese and there was no significant difference in BMI between the
carrier and non-carrier parents (P= 0.15, Student’s t-test).
Furthermore, not only were no deletions identified in a total of
840 subjects from adult severe obesity cohorts (a significant
difference from the overall frequency for child obesity, P= 0.039),
but out of 8 adult carriers from our population cohorts, only 3
were obese. Nevertheless, a further 4 were overweight (BMI
$25 kg.m22) so that, overall, adult carriers had a mean BMI of
30.2 kg.m22 [27.3–33.3], with a mean Z-score (relative to their
respective population distributions) of +1.10 [+0.34–+1.86]
(P= 9.1461024, one-tailed Z-test). The impact of the deletion in
terms of BMI is made clear from comparison of the 4 carriers from
NFBC1966 and the remainder of this cohort (mean BMI
change = +5.8 kg.m22 [+1.5–+10.8]; P= 3.5361023, one-tailed
t-test). Thus, adult carriers of this deletion show an appreciable
increase in BMI, but this is not necessarily sufficient for them to
cross the threshold into clinical obesity.
The original association between this GSV and obesity was
supported by reported disproportionate extreme hyperinsulinae-
mia in carriers of the deletion [10]. We sought to confirm this
finding by investigating fasting insulin and the response to oral
glucose in the subjects from our study. However, we found no
evidence in our cohorts for the reported phenotype. Compared to
the remainder of the cohort from which they were drawn, levels of
fasting insulin in carriers of the deletion were not discernibly
different from those expected for a subject’s BMI, for both
children (Fig. 2a) and adults (Fig. 2b), with no indication of the
reported 3-fold increase; similar conclusions were drawn when the
comparison was limited to individuals of the same gender and age
(Figure S2). Equally, no difference was observed in either fasting
insulin (Fig. 2b) or in the insulin response to oral glucose (Fig. 2c)
between carrier and non-carrier parents of child probands.
Quantitative Trait Replication Analysis
As noted above, a significant association with obesity of
deletions of the SH2B1 locus was identified by quantitative
analysis of BMI in the NFBC1966 population cohort alone, Thus,
the reduced sample size was compensated for by inclusion of
subjects with intermediate phenotypes (i.e. overweight) and the
increase in statistical power that derives from analysis of
quantitative traits compared to case-control approaches to
association testing; indeed, this advantage becomes progressively
more marked at lower allele frequencies for the genetic marker
under test [22]. Therefore, we investigated whether any other
putative GSV-obesity associations were replicated when using this
approach. For each candidate GSV that was identified in at least 3
NFBC1966 subjects – the SH2B1 locus and 5 other loci (Table 1) –
and also the previously-identified 16p11.2 obesity locus, we
Table 2. Replication of obesity association for 220 kb
deletion on chromosome 16p11.2.
Cohort Deletions Total P
Child obesity
Child obesity (France)a 5 645 8.7461027 a
Published data
Severe early-onset obesity (UK) 3 278
GOOS (UK) 2 1,062
CHILD OBESITY TOTALb,c 10 1,985 3.81610210 b
Adult obesity
Adult obesity (France) 0 701
Bariatric weight-loss surgery
(France)
0 139
ADULT OBESITY TOTALc 0 840 0.039 c
General population
NFBC1966 (Finland) 4 5,213
EGCUT (Estonia) 0 2,665
CoLaus (Switzerland) 1 5,612
deCODE (Iceland) 6 36,583
SHIP (Germany) 0 4,068
TOTALa 11 54,141
Published data
WTCCC2/GAIN (UK/US) 2 7,362
ISC/PARC/NINDS/HGDP/CHOP
(Europe/US)
1 7,700
POPULATION TOTALb 14 69,203
Instances of the 220 kb deletion were identified in multiple cohorts by analysis
of SNP genotyping data, with subsequent validation by MLPA or qPCR.
Published data were as according to the respective reports [10,21].
a,b,cDifferences between pairs of combined cohorts, as indicated, were tested
using Fisher’s exact test.
doi:10.1371/journal.pone.0058048.t002
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conducted a 2-way analysis of variance, with gender and GSV
status as explanatory factors and log-transformed BMI as the
response variable. Since several individuals carried more than one
of these GSVs, we also conducted a single, combined, multifac-
torial analysis of these 7 GSVs; this gave very similar results to
those for the separate individual tests. Alternative approaches (e.g.
2-tailed heteroscedastic t-tests using gender-corrected BMI data)
also yielded similar results.
Three loci tested did not give significant association with BMI
although, for two of these, statistical power was limited because
only 3 carriers were identified – this number of carriers permits
only moderate significance (P= 7.45611023) even for the 593 kb
deletions of chromosome 16p11.2 that are known to be strongly
associated with morbid obesity [12,13]. However, in contrast to
the case-control replication analysis, this quantitative approach
provided limited evidence to support involvement in BMI of 2 loci
(in addition to the confirmed association with deletions in the
SH2B1 region), albeit only at or near nominal significance
insufficient to survive correction for multiple-testing. There was
suggestive evidence for association with BMI of duplications near
to the KIF2B gene on chromosome 17q22 (P= 0.103; mean BMI
change =+2.3 kg.m22 [–0.4 – +5.4]); and deletions at a second
locus within the FOXP2 gene on chromosome 7q31.1 were
nominally associated with reduced BMI (P= 0.0476; mean BMI
change = –2.3 kg.m22 [–4.4 – –0.03]). However, this latter effect
was opposite to the increased risk of obesity originally reported
[16].
To investigate these loci in more detail, we assessed the potential
functional impact of the individual GSVs carried by these
individuals. For duplications on chromosome 17q22, all GSVs
identified in our study affected intergenic sequences and covered
the same genomic region as was spanned by the GSVs previously
reported as associated with obesity. However, of the 10 predicted
deletions at the locus on chromosome 7q31.1 that were identified
in our population cohort, 5 extend substantially beyond the GSV
region previously identified as obesity-associated (Figure 3), which
spans 1–3 small exons that (depending on the splice variant)
encode either part of the 59-untranslated region of the FOXP2
mRNA or a small part of the N-terminal of the protein. By
contrast, the larger deletions identified in our analysis are
predicted to include several additional exons and also a possible
binding site (as indicated by ChIP-seq) for transcription factors
including NF-kB, which has been implicated in the regulation of
adipocyte differentiation and proliferation [23]. Thus, these larger
variants may have very different functional effects from the smaller
deletions. Consistent with this, the subjects carrying the 5 largest
putative deletions in this region had significantly reduced BMI
compared to both the population (P= 7.861023, mean BMI
change = –4.2 kg.m22 [–6.8––1.2]) and carriers of the smaller
deletions (P= 0.0177, one-tailed t-test). The smaller variants had
no discernible impact on BMI (P= 0.88).
Discussion
The analysis of rare GSVs for association with complex traits
represents a complementary approach to SNP- or sequence-based
methods for identifying novel loci that can account for the ‘missing
heritability’ of multiple complex traits [3,9]. Even though causal
GSVs themselves may be rare and found only in individuals with
extreme phenotypes, the identification of such GSVs can enable a
more focussed search for rare causal sequence variants. This logic
lay behind the elucidation of the impact on obesity of defects in
SIM1. The original identification of SIM1 as a possible obesity
gene was as a result of its disruption due to a chromosomal
rearrangement (a balanced translocation) in a single individual
with profound obesity [24]; this was followed by the identification,
by exon sequencing, of rare SIM1 variants that co-segregate with
syndromic obesity and of common variants implicated in common
obesity [25,26]. The potential of this approach to reveal additional
novel obesity-associated loci is supported by our analysis, which
provides evidence to support reported GSV associations at 3 loci
[10,16].
Despite being well-powered to confirm the majority of true
associations, and identifying GSVs at similar overall frequencies to
the original reports, only one reported association was confirmed
using a case-control approach. We also conducted tests for
association with BMI as a quantitative trait, for those loci at which
GSVs were identified sufficiently frequently in our population
cohort (for which there was no prior ascertainment on the basis of
obesity). Of 3 GSVs present in .0.1% of subjects, 2 showed
association with changes in BMI at or near nominal significance.
Duplications of a region lying between the KIF2B and TOM1L1
Figure 2. Metabolic phenotype of carriers of a 220 kb deletion at chromosome 16p11.2. (a) Fasting plasma insulin levels relative to BMI,
for 558 normoglycaemic severely obese children from northern France either carrying a deletion (black) or not (grey). (b) Fasting plasma insulin levels
relative to BMI, for 5254 normoglycaemic 31 year-old Finns either carrying a deletion (black circles) or not (grey circles). Also shown are the parents of
obese French child probands who carry a deletion (black triangles) or not (white triangles). (c) Plasma insulin levels in response to a 75 g oral glucose
load in parents of obese child probands. Data shown are mean 6 SEM for carrier parents (n = 3, mean BMI = 28.6 kg.m22, black triangle) and
unaffected parents (n = 4, mean BMI = 27.0 kg.m22, white triangles).
doi:10.1371/journal.pone.0058048.g002
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genes showed marginal association with increased BMI, consistent
with the original report [16]; there is at present no readily
apparent functional basis for this putative association. Intriguingly,
the second nominally-significant association was between deletions
within the FOXP2 gene and decreased BMI, an effect in the
opposite direction to that previously reported for the locus. This
apparent directional inconsistency is likely to be due to the
influence of GSVs that are appreciably larger than those
previously reported, suggesting that the different variants identified
at this locus have widely varying functional effects. A role for
FOXP2 in obesity is supported by the presence within the gene of
independent SNP associations at P,1023 with all of BMI [14],
waist-hip ratio (adjusted for BMI) [15] and insulin resistance [27]
(Figure S3). A plausible basis for association between FOXP2
variants and obesity is through its involvement in neurodevelop-
ment [28], whose importance in feeding behaviour is well-
established [29]; alternatively, an obesity-related phenotype might
be independent of effects on FOXP2, and result instead from
deletion of a putative NF-kB binding site.
Although the 2 associations above provide tentative support for
the original reports that these loci may play a role in obesity, they
are nevertheless insufficient to survive correction for multiple
testing. The only association unambiguously replicated by our
study was that between a 220 kb deletion of chromosome 16p11.2
and obesity. It is interesting to note that this second replicated
locus lies only 600 kb from that previously identified, also on
chromosome 16p11.2, and that both deletions arise de novo with
high frequency, probably reflecting general chromosomal insta-
bility on chromosome 16p due to the presence of multiple
segmental duplications [10,12,21]. The high rate of recurrence of
these deletions likely contributed to their early discovery and
replication using these methods.
We confirm a marked increase in the risk of severe childhood
obesity in carriers of the 220 kb deletion, which accounts for a
total of 0.5% of the combined cases from our study and the
original report. The impact on obesity status in adult carriers
appears less pronounced, but there is nevertheless an appreciable
increase in BMI (corresponding to 15–19 kg in weight for subjects
160–180 cm in height). There are several possible reasons for the
apparent difference between children and adults: it may reflect
population differences (the child carriers of the GSV were from
France and the UK, the adults primarily from Nordic countries); it
may reflect cohort ascertainment, for instance that the child
cohorts did not include overweight or mildly obese subjects – it is
notable, however, that the deletion was not reported at a
comparable frequency in cohorts of children with common obesity
[16]; it may reflect a genuine attenuation of the effect of the
deletion in adults, so that impact of the GSV on obesity becomes
less pronounced with increasing age; or the severe obesity
observed in children may have been triggered by an aspect of
the modern obesogenic environment that was experienced to a
lesser degree by older subjects.
The reported disproportionate hyperinsulinaemia in carriers of
these deletions is reminiscent of the phenotype of SH2B1 knockout
mice [30], which previously led to the suggestion that haploinsuf-
ficiency of SH2B1 is the primary cause of obesity in these
individuals [10]. However, the absence of evidence in our data to
support this phenotype reopens the possibility that haploinsuffi-
ciency of one of the other genes in the region is responsible for the
observed GSV-associated obesity phenotype (although SH2B1
remains a strong candidate). It also highlights the caution required
when interpreting data derived from a heavily-selected cohort –
carriers of a GSV drawn from such a cohort do not necessarily
accurately reflect the phenotypic effect of a GSV in the general
Figure 3. Reduced BMI in carriers of deletions in the FOXP2 region. Deletions within FOXP2 are shown relative to selected tracks from the
UCSC browser (http://genome.ucsc.edu) for the corresponding region of chromosome 7: FOXP2 coding transcripts (UCSC Genes); histone
modifications H3K4Me1, H3K4Me3, H3K27Ac (ENCODE Regulation); and binding by transcription factor NF-kB (ENCODE TFBS). Multiple additional
transcription factors bind at the apparent NF-kB binding site. The minimum extent of each predicted deletion, the probes at which copy number
changes were identified and the BMI for carriers of each deletion are as shown. Grey shading indicates the region previously associated with BMI [16].
doi:10.1371/journal.pone.0058048.g003
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population. We suggest that, if possible, attempts to investigate
additional phenotypes that may be associated with a variant
should not use individuals that have been ascertained on the basis
of the phenotype of interest; instead, they should be drawn from
independent cohorts and selected solely on the basis of being a
carrier of the variant under study.
There are many issues that remain to be addressed when
seeking to identify GSVs that are associated with complex disease,
several of which are highlighted by this study; some of these issues
are also relevant to the analysis of rare variants identified by
sequencing approaches [31,32]. In particular, we make the
following observations and recommendations:
Cohort Selection
Ascertainment according to broad criteria can give only limited
enrichment of rare variants. Conversely, cohorts selected on the
basis of pronounced phenotypes may be difficult to recruit, a
potential problem not only for variant discovery but also for
replication, especially where the discovery cohort includes
individuals not normally recruited to other cohorts (e.g. those
with DD). For instance, we were unable to attempt replication of
GSVs that were originally identified in cases with severe obesity
plus DD since very few of these were detected in our cohorts; some
of these may reflect novel ‘syndromic’ forms of obesity whose
replication will require analysis of additional ‘obesity plus’ cohorts.
We also note that recruitment of cohorts of sufficient size by
including subjects from a range of localities or ethnicities may
introduce complications, since the majority of population groups,
both within Europe and worldwide, have not yet been assessed for
population specific GSVs. This also poses a problem for
replication – the failure to detect some GSVs in our cohorts
may reflect low frequencies in the populations from which they
were drawn. Furthermore, although subjects carrying a highly-
penetrant causative variant might naı¨vely be expected to display
the phenotype regardless of ethnicity, geographical origin or
environmental exposure, we have very little information on the
potential for cohort-specific modifiers that can confound that
expectation, or on differences in the frequencies or characteristics
of rare variants between different populations. As a minimum,
therefore, it is essential to include appropriate geographically-
matched controls (as was the case in the original reports that are
the subject of our replication study).
GSV Detection
In general, large GSVs are more readily detected from
genotyping or CGH array data, but occur infrequently so that
phenotype associations are difficult to demonstrate statistically.
Conversely, accurate calling of smaller GSVs spanning only a few
probes remains problematic, despite ongoing improvements in
methods for GSV detection [19,33,34]. Inaccuracy in GSV calling,
with an appreciable frequency of both false positive and false
negative calls, results in inflated P-values and an increased rate of
false-positive associations (Text S2; Figure S4). This is conceptually
equivalent to other scenarios in which genome-wide inflation occurs
as a result of genotyping inaccuracy [35] – indeed, attempts to apply
algorithmic detection of GSVs to genome-wide genotyping data
yield results with marked inflation [36] (our unpublished observa-
tions) – and we suggest that the appropriate correction is to apply
established methods of genomic control, e.g. scaling of x2 values
according to the genomic inflation parameter l.
Overlapping GSVs and Variable Effects
Although different instances of large GSVs commonly have
approximately the same boundaries [10], with a correspondingly
high probability of having the same or similar phenotypic effects,
smaller GSV regions routinely feature a range of overlapping GSV
calls of different sizes and locations [36,37], thereby presenting a
dilemma – in the absence of strong prior information to enable
modelling of the effects of different GSV variants, how should a
range of variants affecting a single locus be combined when testing
for association with a phenotype of interest? One approach,
analogous to methods such as the ‘cohort allelic sums test’ [38]
developed for analysis of multiple rare sequence variants within a
gene, is to treat a set of overlapping GSVs as functionally identical,
effectively discounting the structural complexity, so that only a
single hypothesis related to a putative functional effect is tested.
Although perhaps appropriate where, for instance, all variants are
predicted to have similar functional consequences due to directly
disrupting or deleting a particular gene or due to affecting an
intergenic region, this approach requires user intervention and is
not universally applicable (e.g. in the context of a genome-wide
analysis). A more general unsupervised approach for analysis of
such complex loci, used in the studies examined here [10,16] and
also in analyses of common GSVs [36,37,39], is to test separately
at multiple probe locations within a region. However, as illustrated
by our analysis of the FOXP2 locus, it cannot be assumed that
overlapping but distinct variants have similar effect sizes or even
directions; furthermore, such ‘point-wise’ analysis entails multiple
statistical tests at each GSV locus, leading to potential inflation in
the reported P-value for the region as a whole. Thus, there is a
need for methods that properly address the structural complexity
frequently observed at GSV loci. One straightforward approach
might be to apply a locus-specific multiple-testing correction,
according to GSV complexity, to reflect the number of indepen-
dent tests made at a locus, in a manner similar to that used to
correct for multiple tests of SNPs in linkage disequilibrium [40].
Alternatively, more sophisticated methods developed for aggre-
gating rare sequence variants in the absence of prior information,
for instance as implemented in the ‘thgenetics’ R package [41],
might be adapted for use with complex GSVs.
Although problematic for the identification of an association, we
nevertheless note that the existence of multiple different GSVs
may be of great utility in dissecting a locus whose association has
been conclusively demonstrated.
Statistical Power and False Discovery
Even after enrichment by selection of an appropriate discovery
cohort, and testing only for rare GSVs with dominant phenotypic
effects, low statistical power remains an important issue, with
increased rates of false negative and false positive associations at a
given significance threshold and inflated estimates of effect size
(‘‘winner’s curse’’) [20,31,32]. As noted above, increasing cohort
size to give improved power and/or reduced type I error rate may
not be readily achievable for highly specific phenotypes. A second
statistical issue, common to all scans for variant associations, is that
each of the many GSVs detected in even a small cohort is the
subject of a separate independent hypothesis, so that substantial
multiple testing correction of the significance threshold or rigorous
control of the false discovery rate (FDR) is required if a large type I
error rate is to be avoided. Even after the use of predefined criteria
to select a subset of GSVs for analysis, the necessary correction
remains substantial: In the previous studies, subjects with common
obesity carried approximately 20 GSV calls per individual (1080
cases, 2500 controls) [16]; more than 300 separate rare GSV loci
were identified in the extreme obesity discovery cohort alone [10];
and both used a point-wise method for assessing association at
complex GSV regions. Although attempts were made to take
account of multiple testing (e.g. exclude GSVs present in the
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Database of Genomic Variants, including only rare GSVs,
empirical estimate of FDR), it is unclear to what extent these
methods are effective – methods developed for association analysis
of rare sequence variants are not consistently well-powered even
for large sample sizes [42]. Indeed, inspection of the original
overall P-values for each GSV (Table 1: reproduced from or
calculated according to the original reports; see Text S1) shows
that even a moderate correction to the threshold for significance to
account for these multiple tests would have excluded the majority
of the reported loci. Thus, our observation of an apparent high
rate of false positives is likely to reflect insufficient control of the
FDR.
We suggest that a potentially useful approach is to adopt a two-
stage study design: initial genome-wide analysis of case-control
cohorts for GSV discovery, although likely to be underpowered,
will nevertheless yield a set of candidate GSVs; unselected
population cohorts can then be screened for individuals carrying
these GSVs. The key advantage of this approach is that carriers
identified from population cohorts are not biased (either qualita-
tively or quantitatively) by pre-existing ascertainment criteria, so
that the impact of the GSV on phenotype can be directly analysed
using more powerful quantitative methods.
Our replication of the obesity association of deletions including
SH2B1 and the finding of limited evidence to support 2 further
associations, together with recent successes in other disorders
including attention deficit hyperactivity disorder [43], demonstrate
that analysis of carefully-selected cohorts has the potential to
reveal novel, rare, causal GSVs. However, it is clear that there
remains a need for an accepted foundation on which to base
genome-wide searches for rare variants. In its absence, attempts to
overcome the unavoidable lack of statistical power may lead to the
adoption of methods whose effectiveness is not readily quantifi-
able. Thus, there is a danger that reported associations may
include a large number of false positives. Similar caveats should
perhaps also be attached to the growing number of studies
investigating common GSVs [36,37,39]. Although careful exper-
imental design and the inclusion of additional phenotypic and/or
experimental data can help to limit this problem, our findings
illustrate the urgent need for well-defined, robust statistical
methods that are readily applicable to the search for causal, rare,
genomic structural variants.
Materials and Methods
Cohorts
Initial replication analysis was of cohorts used in our previous
work [12], with ethnic outliers removed as described. Obesity
case-control cohorts from France were as previously published
[17]: Phenotypes and genotyping data (Illumina Human
CNV370-duo arrays) passing quality control were available for
649 obese children with a body mass index (BMI) $97th percentile
corrected for gender and age; 557 non-obese controls (BMI #90th
percentile); 705 obese adults (BMI $40 kg.m22) and 843 non-
obese controls (,25 kg.m22). Data for 141 severely obese French
patients undergoing elective bariatric weight-loss surgery were as
previously described [12]. For The Northern Finland Birth Cohort 1966
(NFBC1966) prospective birth cohort [18], phenotypic data and
genotyping data (Illumina Human CNV370-duo arrays) passing
quality control was available for 5,216 subjects aged 31 years at
the time of phenotyping. For further replication of the 220 kb
deletion on chromosome 16p11.2, genotyping data was available
for other previously-described population cohorts as follows: the
CoLaus prospective population cohort [44] –5,612 white individ-
uals aged 35–75 years randomly selected from the general
population in Lausanne, Switzerland; the EGCUT BioBank [45]
–2,666 individuals randomly selected from the 48,000 Estonian
participants; the deCODE population cohort [46]–36,601 recruited
from the whole of Iceland; the SHIP cross-sectional survey cohort
[47,48] –4,070 German citizens from Western Pomerania. In all
cases, individuals in the above cohorts were excluded from the
analysis if they had previously been shown to carry single-locus
obesity variants (e.g. in MC4R); specifically excluded were those
carrying the obesity-causing deletion of 593 kb on chromosome
16p11.2 (4 child obesity, 4 adult obesity, 2 bariatric patients, 3
NFBC1966, 1 EGCUT, 18 deCODE, 2 SHIP) [12]; no subject
was related to any other subject. All participants or their legal
guardians gave written informed consent, and all local ethics
committees approved the study protocol. EGCUT is conducted
according to Estonian Gene Research Act. For deCODE, all
procedures related to this study have been approved by the Data
Protection Authority and National Bioethics Committee of
Iceland.
GSV Identification
The GSV regions were selected either as stated in the original
report [16] or the region common to all GSVs identified in that
region [10], and were analysed according to the GSV analysis
pipeline illustrated in Figure 1. Intensity data from the French and
NFBC1966 cohorts were exported from Illumina BeadStudio in
the form of logR ratio (LRR) and B Allele Frequency (BAF);
samples with a low SNP call rate (,95%) or a genome-wide LRR
variance .0.3 were excluded. The cnvHap algorithm with default
parameter settings (false discovery rate ,5%) was applied to each
region under investigation plus additional 500 kbp flanking
regions; using these parameters we expect high sensitivity for
GSV detection – even a false discovery rate as low as 1% gives
genome-wide sensitivity of ,40% for GSV detection in an
individual, and .60% for identifying the presence of a GSV in a
cohort [19]. The initial (unsupervised) GSV detection was further
improved by a series of manual procedures applied to each GSV
locus under study: Only GSV calls covering at least 3 consecutive
probes were considered; for short GSV regions spanning 6 or
fewer probes, GSV calls were required to span the entire region;
and SNP cluster plots were manually inspected to confirm both
positive and negative GSV calls and to check for possible
artefactual sources of differential GSV detection between cases
and controls. For longer GSV regions (i.e. spanning $11 probes),
it was also necessary to manage the effects of data noise or of the
presence of a second small GSV in the same location on the
homologous chromosome on GSV calling; a side-effect of the
improved sensitivity of cnvHap is that, particularly for samples
with lower data quality, larger GSVs are sometimes split into
several smaller GSV calls. Thus, a modified procedure was
employed: GSV calls across the entire region were combined, and
individuals with copy number changes (i.e. deletion or duplication,
as appropriate) at over 50% of probes within the region were
provisionally called as carrying a GSV; the presence of a full-
length GSV in these individuals was then confirmed by manual
inspection of the LRR and BAF data. This approach again
minimises the potential for artefactual associations arising from
different GSV call-rates in cases and controls (e.g. due to
differences in DNA quality). Furthermore, for both adult and
child case-control cohorts, any potential bias in GSV detection
favoured an increased call rate in cases (higher mean number of
GSV calls per subject) which would be expected to favour false
positive associations and to mitigate against false negatives. All
chromosomal coordinates are given according to genome build 36
(hg18).
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Screening for the 220 kb deletion on chromosome 16p11.2 in
GWAS data from additional cohorts was variously carried out
using a Gaussian Mixture Model [49]; Circular Binary Segmen-
tation [50,51]; QuantiSNP [52]; PennCNV [53]; BeadStudio GT
module (Illumina Inc); and Birdseed [54]. At least two indepen-
dent methods were used for each cohort. Where DNA was
available, GSV calls at this locus were confirmed and probands’
parents investigated by multiplex ligation-dependent probe am-
plification [55], using the oligonucleotide probe set previously
described [10] (kind gift of I.S. Farooqi).
Fasting Insulin and Oral Glucose Tolerance test
Data for insulin, after fasting and following 75 g oral glucose,
were from previously-reported studies [18,56]. Plasma insulin was
assayed by radioimmunoassay (Pharmacia Diagnostics) in blood
samples drawn either after overnight fasting or at 0, 30, 60, 90,
and 120 min after glucose ingestion.
Statistics
Tests for case-control association and calculation of odds ratios
were carried out using the fisher.test function, tests for differences
in log-transformed BMI used the analysis of variance aov function,
and Z-test for deviation from population mean used the Student’s
t-test t.test function, each as implemented in R [57]. Calculations
of post-hoc achieved power for one-tailed Fisher’s exact test were
carried out using G*Power version 3.1.2 [58].
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